HK Stock Market Move | Guangzhou Baiyunshan Pharmaceutical Holdings (00874) rose nearly 3% recently and is planning to establish the Guangzhou Pharmaceutical Capital Fund II with Guangzhou Pharmaceutical Capital to increase its efforts in incubating and investing in the medical and health industry.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) rose nearly 3%, reaching 2.76% by the time of the report, at HK$18.62, with a trading volume of HK$62.9348 million. In terms of news, Guangzhou Baiyunshan Pharmaceutical Holdings announced that on July 25, 2025, the company entered into a partnership agreement with Guangzhou Pharmaceutical Capital. Under this agreement, the company and Guangzhou Pharmaceutical Capital will each invest RMB 1.4985 billion and RMB 1.5 million to establish Guangzhou Fund Phase II. The company will effectively control Guangzhou Fund Phase II, and its financial performance will be included in the company's consolidated financial statements. The purpose of the partnership and fund allocation is to carry out equity investments in the biopharmaceutical field through direct or indirect means to earn investment returns. Mainly focusing on the company's strategic planning, investments will be made in the biopharmaceutical and health sectors through subsidiary fund investments, direct project investments, etc. The establishment of Guangzhou Fund Phase II aims to seize industry development opportunities, accelerate the company's industrial layout in the biopharmaceutical and health fields, and increase the company's investment efforts in the pharmaceutical and health industries.